Sitafloxacin (DU-6859a) and trovafloxacin: Postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus

Diagnostic Microbiology and Infectious Disease

Volumn 34, Issue 4, 1999, Pages 301-307

  Giamarellou Bourboulis, Evangelos J ^a   Sambatakou, Helen ^b   Grecka, Paraskevi ^a   Chryssouli, Zoi ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; RIFAMPICIN; SITAFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; DOSE RESPONSE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; FLUOROQUINOLONES; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; RIFAMPIN; STAPHYLOCOCCUS AUREUS;

EID: 0032791585     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00044-9     Document Type: Article

References (16)

1. Andrews J.M., Honeybourne D., Brenwald N.P., Bannerjee D., Iredale M., Cunningham B., Wise R. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 39:1997;797-802.
2. Boswell FJ, Andrews JM, Wise R (1997) Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa. J Antimicrob Chemother 39:811-814.
3. Brighty K.E., Gootz T.D. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 39:(suppl B):1997;1-14.
4. Craig W.A., Gudmundsson S. Postantibiotic effect. Lorian V. Antibiotics in Laboratory Medicine, 3rd Ed. 1991;403-431 Williams & Wilkins, Baltimore.
5. Giamarellou-Bourboulis E.J., Grecka P., Galani I., Giamarellou H. Comparative in-vitro activity and killing effect of trovafloxacin, DU-6859a, levofloxacin and sparfloxacin against Staphylococcus aureus. Focus on methicillin-resistant isolates. Clin Drug Invest. 14:1997;330-337.
6. Hindler J (1992) Tests to detect oxacillin (methicillin) resistant staphylococci with an oxacillin screen plate. In: Clinical Microbiology Procedures Handbook. Ed, Eisenberg HD. Washington, DC: American Society for Microbiology, pp. 5.5.1-5.5.7.
7. Hindler J (1992) Tests to assess bactericidal activity. In: Clinical Microbiology Procedures Handbook. Ed, Eisenberg HD. Washington, DC: American Society for Microbiology, pp. 5.16.14-5.16.24.
8. Morrisey I. Bactericidal activity of trovafloxacin (CP-99,219). J Antimicrob Chemother. 38:1996;1061-1066.
9. Moses L.E., Emerson J.D., Hosseini H. Analyzing data from ordered categories. Baillar J.C. III, Mosteller F. Medical Uses of Statistics, 2nd Ed. 1992;259-279 Massachusetts Medical Society, Boston.
10. Nakashima M., Uematsu T., Kosuge K., Umemura K., Hakusui H., Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 39:1995;170-174.
11. Nakane T., Iyobe S., Sato K., Mitsuhashi S. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother. 39:1995;2822-2826.
12. Pankuch G.A., Jacobs M.R., Appelbaum P.C. Postantibiotic effect of trovafloxacin against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 42:1998;1503-1505.
13. Sambatakou H., Giamarellos-Bourboulis E.J., Grecka P., Chryssouli Z., Giamarellou H. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother. 41:1998;349-355.
14. Wise R., Motriboy D., Child J., Andrews J.M. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother. 40:1996;47-49.
15. Woods G.L., Washington J.A. Antibacterial susceptibility tests Dilution and disk diffusion methods . Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yoken R.H. Manual of Clinical Microbiology, 6th Ed. 1995;1327-1341 American Society for Microbiology, Washington, DC.
16. Zelterman D., Louis T.A. Contigency tables in medical studies. Baillar J.C. III, Mosteller F. Medical Uses of Statistics, 2nd Ed. 1992;2293-2310 Massachusetts Medical Society, Boston.